Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial.
paper
Cited
Public
Unavailable
- Authors
- Johnstone, Elaine C; Elliot, Katherine M; David, Sean P; Murphy, Michael F G; Walton, Robert T; Munafò, Marcus R
- Year
- 2007
- Journal
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- PMID
- 17548664
- DOI
- 10.1158/1055-9965.EPI-06-0936
- PMCID
- PMC2031911
We investigated the association of catechol O-methyltransferase (COMT) genotype with abstinence following a smoking cessation attempt among a large cohort of smokers who attempted to quit using either the nicotine transdermal patch or placebo and were followed up over an 8-year period following their initial cessation attempt. In addition, we examined the possible moderating influence of sex on any association. The genotype x treatment interaction effect at 12-week follow-up indicated a greater benefit of active nicotine replacement treatment compared with placebo on likelihood of abstinence in the COMT Met/Met genotype group (33% versus 12%), in comparison to the Met/Val + Val/Val group (22% versus 16%). Our results indicate that COMT genotype may moderate the effect of active transdermal nicotine patch compared with placebo, with reduced relative benefit of nicotine replacement therapy in individuals with Met/Val or Val/Val genotype. Our data follow an emerging pattern of results suggesting that genetic variation in the dopamine pathway may provide a future basis for tailored smoking cessation therapies, but indicate that different genes influencing various components of this pathway may have different effects on response to smoking cessation pharmacotherapy.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| The genetic epidemiology of substance use disorder: A review. | 2017 | 28938182 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Association of monoaminergic gene polymorphisms in chronic inflammatory pulmonary disease patients with successful smoking cessation. | Mikaczo A et al. | — | 2024 | → |
| Single Nucleotide Polymorphisms Within <i>DRD2, COMT, and DBH</i> and Smoking Cessation: A Systematic Review Considering Genetic Differences by Ancestry and Biological Sex. | Jones SK et al. | — | 2024 | → |
| The association of genetic polymorphisms within the dopaminergic system with nicotine dependence: A narrative review. | Yang J et al. | — | 2024 | → |
| A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations. | Prom-Wormley EC et al. | — | 2023 | → |
| Catechol-O-Methyltransferase Effects on Smoking: A Review and Proof of Concept of Sex-Sensitive Effects. | DeVito EE et al. | — | 2022 | → |
| Neurogenetic determinants and mechanisms of addiction to nicotine and smoked tobacco. | Sharp BM et al. | — | 2019 | → |
| Systems pharmacogenomics - gene, disease, drug and placebo interactions: a case study in COMT. | Hall KT et al. | — | 2019 | → |
| From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. | Salloum NC et al. | — | 2018 | → |
| Interaction Between Environmental Risk Factors and Catechol-O-Methyltransferase (COMT) and X-Ray Repair Cross-Complementing Protein 1 (XRCC1) Gene Polymorphisms in Risk of Lung Cancer Among Non-Smoking Chinese Women: A Case-Control Study. | Pan JL et al. | — | 2018 | → |
| Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. | Schuit E et al. | — | 2017 | → |
| The genetic epidemiology of substance use disorder: A review. | Prom-Wormley EC et al. | — | 2017 | → |
| What does addiction medicine expect from neuroscience? From genes and neurons to treatment responses. | Le Foll B | — | 2016 | → |
| A review of pharmacogenetic studies of substance-related disorders. | Jones JD et al. | — | 2015 | → |
| Association between catechol-O-methyltransferase (COMT) Val/Met genotype and smoking cessation treatment with nicotine: a meta-analysis. | Choi HD et al. | — | 2015 | → |
| Addiction science: Uncovering neurobiological complexity. | Volkow ND et al. | — | 2014 | → |
| Cognitive function during nicotine withdrawal: Implications for nicotine dependence treatment. | Ashare RL et al. | — | 2014 | → |
| Pharmacogenetics of nicotine addiction: role of dopamine. | Herman AI et al. | — | 2014 | → |
| A preliminary study suggests that nicotine and prefrontal dopamine affect cortico-striatal areas in smokers with performance feedback. | Lee MR et al. | — | 2013 | → |
| Association of abstinence-induced alterations in working memory function and COMT genotype in smokers. | Ashare RL et al. | — | 2013 | → |
| Effects of intravenous nicotine on prepulse inhibition in smokers and non-smokers: relationship with familial smoking. | Drobes DJ et al. | — | 2013 | → |
| Environmental and genomic factors as well as interventions influencing smoking cessation: a systematic review of reviews and a proposed working model. | de Viron S et al. | — | 2013 | → |
| Predicting the cost and pace of pharmacogenomic advances: an evidence-based study. | Arnaout R et al. | — | 2013 | → |
| Association between nicotinic acetylcholine receptor single nucleotide polymorphisms and smoking cessation. | Spruell T et al. | — | 2012 | → |
| Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy. | Sun H et al. | — | 2012 | → |
| Effects of COMT polymorphisms on brain function and behavior in health and disease. | Witte AV et al. | — | 2012 | → |
| Association of COMT Val(108/158)Met genotype and cigarette smoking in pregnant women. | Munafò MR et al. | — | 2011 | → |
| Biomarkers to optimize the treatment of nicotine dependence. | Schnoll RA et al. | — | 2011 | → |
| CHRNA3 rs1051730 genotype and short-term smoking cessation. | Munafò MR et al. | — | 2011 | → |
| Pharmacogenetics of alcohol, nicotine and drug addiction treatments. | Sturgess JE et al. | — | 2011 | → |
| Pharmacogenetics of smoking cessation in general practice: results from the patch II and patch in practice trials. | David SP et al. | — | 2011 | → |
| Relapse prevention for addictive behaviors. | Hendershot CS et al. | — | 2011 | → |
| Treatment for tobacco dependence: a potential application for stratified medicine? | Brock AJ et al. | — | 2011 | → |
| Are genetic variants of COMT associated with addiction? | Tammimäki AE et al. | — | 2010 | → |
| Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. | Wang J et al. | — | 2010 | → |
| Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. | Ray R et al. | — | 2010 | → |
| Determination of Methylated CpG Sites in the Promoter Region of Catechol-O-Methyltransferase (COMT) and their Involvement in the Etiology of Tobacco Smoking. | Xu Q et al. | — | 2010 | → |
| Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. | De Ruyck K et al. | — | 2010 | → |
| Pharmacogenetics of smoking cessation therapy. | Kortmann GL et al. | — | 2010 | → |
| Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype. | Loughead J et al. | — | 2009 | → |
| Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases? | Quaak M et al. | — | 2009 | → |
| Implications of gene-drug interactions in smoking cessation for improving the prevention of chronic degenerative diseases. | Quaak M et al. | — | 2009 | → |
| Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. | Munafò MR et al. | — | 2009 | → |
| Nicotine dependence: biology, behavior, and treatment. | Ray R et al. | — | 2009 | → |
| Sex heterogeneity in pharmacogenetic smoking cessation clinical trials. | Schnoll RA et al. | — | 2009 | → |
| The effect of catechol-O-methyltransferase Met/Val functional polymorphism on smoking cessation: retrospective and prospective analyses in a cohort study. | Omidvar M et al. | — | 2009 | → |
| Association of COMT Val108/158Met genotype with smoking cessation. | Munafò MR et al. | — | 2008 | → |
| Genetic variation in the dopamine pathway and smoking cessation. | David SP et al. | — | 2008 | → |
| Neuroimaging, genetics and the treatment of nicotine addiction. | Ray R et al. | — | 2008 | → |